GRAIL, Inc.
NASDAQ:GRALMedical - Diagnostics & Research
+$1.90 today
- Market cap
- $4.59B
- Beta
- 3.16
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$9.73
Volume 0.62M
Average 0.77M
GRAL Total Liabilities
Everything the company owes to creditors and other parties.
GRAIL, Inc.NASDAQ: GRAL
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities falls 22.4% from a year ago
Total liabilities stood at $301.03M at the end of Q2 FY2026, down 22.4% from a year earlier and down 0.6% from the prior quarter. Over 3 fiscal years it compounded at -28.9% a year.
Context
- Total liabilities amounted to 10.6% of total assets at the end of Q2 FY2026, down 3.8 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -22.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 344.15M USD
- Year-over-year change
- -28.3%
- 4-year CAGR
- +2.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 344.15M | -28.3% |
| FY2024 | 2024-12-31 | 479.9M | -47.3% |
| FY2023 | 2023-12-31 | 910.74M | -4.7% |
| FY2022 | 2022-12-31 | 955.94M | +211.0% |
| FY2021 | 2021-12-31 | 307.4M | — |
Total Liabilities vs competitors
How GRAL compares with its peers on the latest reported figures
- GRAL's Jun 2026 total liabilities of $301.03M is the 5th highest of the 10 companies compared; the peer median is $237.27M.
- Its year-over-year change of -22.4% is the lowest of 10, against a peer median of +32.5%.
- Total liabilities amounts to 10.6% of total assets for GRAL, versus a peer median of 31.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.16B | +32.5% | +10.9% | 114.6% | |
| Jun 2026 | $836M | +63.6% | +4.9% | 31.5% | |
| Jun 2026 | $565.65M | +4.8% | -11.0% | 41.8% | |
| Mar 2026 | $336.3M | +11.7% | +2.7% | 49.9% | |
| Jun 2026 | $301.03M | -22.4% | -28.9% | 10.6% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $237.27M | +27.1% | -3.5% | 49.3% |
BLLNBillionToOne, Inc. | Jun 2026 | $192.89M | +34.4% | — | 26.4% |
| Mar 2026 | $112.22M | +35.2% | -2.8% | 9.7% | |
| Mar 2026 | $86.39M | +40.7% | +30.7% | 15.8% | |
| Mar 2026 | $70.63M | +7.1% | -0.7% | 21.7% | |
| Peer median (excluding GRAL) | $237.27M | +32.5% | +1.0% | 31.5% | |
Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 221.16M | 241.6M | 97.29M | 214.23M | 249.73M |
| Short-term Investments | 0 | 0 | 0 | 549.24M | 654.7M |
| Net Receivables | 6.88M | 18.62M | 22.35M | 24.64M | 18.3M |
| Inventory | 0 | 19.76M | 21.7M | 18.63M | 16.02M |
| Other Current Assets | 6.89M | 0 | 0 | 0 | 15.11M |
| Total Current Assets | 242.73M | 295.63M | 156.07M | 819.86M | 953.85M |
| Property, Plant & Equipment (Net) | 216.37M | 198.72M | 169.38M | 135.43M | 103.88M |
| Goodwill | 6.2B | 1.5B | 888.94M | 0 | 0 |
| Intangible Assets | 3.07B | 2.94B | 2.69B | 2.02B | 1.85B |
| Long-term Investments | 0 | 4.53M | 4.23M | 0 | 6.97M |
| Tax Assets | 0 | 664.12M | 643.11M | 0 | 0 |
| Other Non-current Assets | 7.1M | 6.14M | 7.98M | 11.12M | 6.75M |
| Total Non-current Assets | 9.5B | 5.31B | 4.4B | 2.16B | 1.97B |
| Total Assets | 9.74B | 5.6B | 4.56B | 2.98B | 2.92B |
| Account Payables | 17.65M | 17.48M | 19.67M | 4.84M | 2.08M |
| Short-term Debt | 0 | 13.34M | 14.81M | 0 | 11.72M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 1.6M | 0 |
| Other Current Liabilities | 4.51M | 65.96M | 87.64M | 22.69M | 65.87M |
| Total Current Liabilities | 97.89M | 134.94M | 163.61M | 76.93M | 79.67M |
| Long-term Debt | 0 | 0 | 0 | 0 | 43.15M |
| Deferred Tax Liabilities | 0 | 735.19M | 676.03M | 345.86M | 218.58M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 112.76M | 3.13M | 1.5M | 2.24M | (40.4M) |
| Total Non-current Liabilities | 209.51M | 821M | 747.13M | 402.98M | 264.48M |
| Total Liabilities | 307.4M | 955.94M | 910.74M | 479.9M | 344.15M |
| Common Stock | 10.34B | 10.96B | 11.42B | 34K | 40K |
| Retained Earnings | (911.54M) | (6.31B) | (7.78B) | (9.8B) | (10.21B) |
| Accumulated OCI | 315K | 894K | 1.07M | 1.45M | 2.66M |
| Other Stockholders Equity | 1 | 0 | 1 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 9.43B | 4.65B | 3.65B | 2.5B | 2.58B |
| Total Debt | 110.56M | 96.01M | 84.41M | 68.14M | 98.01M |
| Net Debt | (110.6M) | (145.59M) | (12.88M) | (146.09M) | (151.72M) |
GRAIL, Inc.
NASDAQ:GRAL
Intrinsic Alpha fair value
Locked
Current Price
$102.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.